Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.36 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.34 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.32 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3621192 | 0.81 | DYRK1A (0.44) | DYRK1ASCN5AALDH1A1TGFBR1PIK3CD | |
| SCHEMBL30014450 | 0.76 | DYRK1A (0.51) | DYRK1ASCN5ATGFBR1PIK3CDPDE4B | |
| SCHEMBL749404 | 0.76 | DYRK1A (0.51) | DYRK1ASCN5ATGFBR1PIK3CDPDE4B | |
| SCHEMBL22228628 | 0.72 | PIK3CD (0.36) | DYRK1AALDH1A1KDM4ESMN1; SMN2TGFBR1 | |
| SCHEMBL21618264 | 0.72 | ALDH1A1 (0.36) | DYRK1AALDH1A1KDM4ESMN1; SMN2KCNJ1 | |
| SCHEMBL708700 | 0.72 | NPC1 (0.48) | DYRK1ASCN5AALDH1A1KDM4ETGFBR1 | |
| SCHEMBL708701 | 0.72 | NPC1 (0.48) | DYRK1ASCN5AALDH1A1KDM4ETGFBR1 | |
| SCHEMBL30014056 | 0.71 | TGFBR1 (0.53) | DYRK1ASCN5ATGFBR1PIK3CDPDE4B | |
| SCHEMBL4553627 | 0.70 | DYRK1A (0.39) | DYRK1ASCN5ATGFBR1PIK3CDPDE4B | |
| Hydrochloric Acid SCHEMBL31132579 | 0.70 | PIK3CD (0.35) | DYRK1AALDH1A1KDM4ESMN1; SMN2TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133876-A1 | FLUORINE-FREE CLEANING AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF | 嘉庚创新实验室 | 2023-07-20 | — | — | WO | claimed |
| EP-3600294-B1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | CLAVIUS PHARMACEUTICALS LLC (US) | 2025-09-03 | — | — | EP | disclosed |
| US-12006315-B2 | Intermediate useful for the synthesis of TGF-beta inhibitors and a method of preparing TGF-beta inhibitors using the same | MEDPACTO INC. (KR) | 2024-06-11 | — | — | US | disclosed |
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230303568-A1 | INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME | MEDPACTO INC. (KR) | 2023-09-28 | — | — | US | disclosed |
| CN-116804009-A | Intermediate for synthesizing TGF-beta inhibitor and method for preparing TGF-beta inhibitor by using intermediate | 株式会社麦迪帕克特 | 2023-09-26 | — | — | CN | disclosed |
| WO-2023133876-A1 | FLUORINE-FREE CLEANING AGENT, PREPARATION METHOD THEREFOR AND USE THEREOF | 嘉庚创新实验室 | 2023-07-20 | — | — | WO | disclosed |
| US-20220073514-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | Clavius Pharmaceuticals, LLC. | 2022-03-10 | — | — | US | disclosed |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | Clavius Pharmaceuticals, LLC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210154188-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-27 | — | — | US | disclosed |
| WO-2008094556-A2 | IMIDAZOLONE COMPOUNDS AS TGF-BETA FAMILY TYPE I RECEPTORS, ALK5 AND/OR ALK4 ANTAGONISTS | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008094574-A2 | FURANONE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BIOGEN IDEC MA INC. (US) | 2008-08-07 | — | — | WO | disclosed |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | LEE WEN-CHERNG | 2008-07-17 | — | — | US | disclosed |
| WO-2008047229-A2 | BIARYL ETHER UREA COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| WO-2007059359-A2 | SUBSTITUTED PYRAZALONES | BIOGEN IDEC MA INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| EP-1786803-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | Biogen Idec MA, Inc. (US) | 2007-05-23 | — | — | EP | disclosed |
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | BIOGEN MA INC. | 2006-03-23 | — | — | US | disclosed |
| WO-2006026305-A1 | PYRIMIDINYLPYRAZOLES AS TGF-BETA INHIBITORS | BIOGEN IDEC MA INC (US) | 2006-03-09 | — | — | WO | disclosed |
| EP-1499308-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2003087304-A2 | TRI-SUBSTITUTED HETEROARYLS AND METHODS OF MAKING AND USING THE SAME | BIOGEN, INC. (US) | 2003-10-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12006315-B2 | Intermediate useful for the synthesis of TGF-beta inhibitors and a method of preparing TGF-beta inhibitors using the same | TGFB1, TGFBR1, TGFB2 | DYRK1A 4658/4885SCN5A 2811/4885ALDH1A1 355/4885 |
| US-20060063809-A1 | Tri-substituted heteroaryls and methods of making and using the same | ALK, ACVR1, ACVRL1 | DYRK1A 1587/4885SCN5A 421/4885ALDH1A1 113/4885 |
| US-20230303568-A1 | INTERMEDIATE USEFUL FOR THE SYNTHESIS OF TGF-BETA INHIBITORS AND A METHOD OF PREPARING TGF-BETA INHIBITORS USING THE SAME | TGFB1, TGFBR1, TGFB2 | DYRK1A 4658/4885SCN5A 2811/4885ALDH1A1 355/4885 |
| US-11124509-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | DYRK1A 2769/4885SCN5A 2937/4885ALDH1A1 1635/4885 |
| US-20220073514-A1 | TRI-SUBSTITUTED IMIDAZOLES FOR THE INHIBITION OF TGF BETA AND METHODS OF TREATMENT | TGFB1, TGFBR1, TGFB2 | DYRK1A 2769/4885SCN5A 2937/4885ALDH1A1 1635/4885 |
| US-11845745-B2 | Tri-substituted imidazoles for the inhibition of TGF beta and methods of treatment | TGFB1, TGFBR1, TGFB2 | DYRK1A 2769/4885SCN5A 2937/4885ALDH1A1 1635/4885 |
| US-20210154188-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ALKBH3 | DYRK1A 2248/4885SCN5A 767/4885ALDH1A1 120/4885 |
| US-20080171755-A1 | Pyrimidinylpyrazoles as Tgf-Beta Inhibitors | TGFBR1, SMAD3, ALK | DYRK1A 3927/4885SCN5A 678/4885ALDH1A1 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.